Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice

Based on our previous findings that medroxyprogesterone acetate (MPA) significantly suppressed the formation of preneoplastic mammary hyperplastic alveolar nodules in mice, and that this suppression persisted for some time, we studied the effects of different schedules of MPA treatment on spontaneous mammary tumorigenesis and uterine adenomyosis in SHN virgin mice. Mice received a subcutaneous pellet of MPA every 2 months: I) during the limited period of 1–3 months of age; II) throughout the experiment beginning at 6–8 months of age; and III) throughout the experiment beginning at 2–3 months of age. All treatments significantly enhanced mammary tumorigenesis with little difference in the effects among treatments. The progression of uterine adenomyosis was also stimulated in Experiments I and III, but not in Experiment II. These results are in good accord with our previous observations with progesterone, indicating that MPA has progesterone-like effects on mammary and uterine lesions of mice.

Formelli F, Zaccheo T, Mazzoni A, Isetta AM, Casazza AM, Di Marco A: Antitumour activity and pharmacokinetics of medroxyprogesterone acetate in experimental mammary tumour systems. In: Cavalli F, McGuire WL, Pannuti F, Pellegrini A, Robustelli Della Cuna G (eds) Proceedings of the International Symposium on Medroxyprogesterone Acetate. Excerpta Medica, Princeton, 1982, pp 47–62 Danguy A, Legros N, Leclercq G, Heuson JC: Effects of medroxyprogesterone acetate on the development of dimethyl-benzanthracene-induced mammary tumours: possible modes of action. In: Cavalli F, McGuire WL, Pannuti F, Pellegrini A, Robustelli Della Cuna G (eds) Proceedings of the International Symposium on Medroxyprogesterone Acetate. Excerpta Medica, Princeton, 1982, pp 63–76 Zaccheo T, Casazza AM, Di Salle E, Pollini C, Di Marco A: Combined and sequential treatment using FCE 21336, a new prolactin-lowering drug, and medroxyprogesterone acetate (MPA) in DMBA-induced tumors in rats. Eur J Cancer Clin Oncol 20: 1193–1197, 1984 Tominaga T, Yoshida Y, Kitamura M, Kosaki G: Effective sequential administration of tamoxifen and medroxyprogesterone acetate for 7,12-dimethylbenz[a]anthracene-in-duced rat mammary tumors in relation to hormone receptors. Jpn J Cancer Res (Gann) 76: 1120–1125, 1985 Racca S, Conti G, Crispino A, Gallo E, Di Carlo F: Effects of medroxyprogesterone acetate on DMBA-induced mammary tumors. Chemoterapia 4: 236–238, 1985 Nagasawa H: Comparison of mouse and rat mammary tumors as animal models for human breast cancer: An autobiographic research essay. The 40th Anniversary Issue of the Foundation of the School of Agriculture, Meiji University, 1986, pp 71–85 Nagasawa H, Fujii M., Hagiwara K: Inhibition by medroxyprogesterone acetate of precancerous mammary hyperplastic alveolar nodule formation in mice. Breast Cancer Res Treat 5: 31–36, 1985 Mori T, Nagasawa H, Takahashi S: The induction of adenomyosis in mice by intra-uterine pituitary isografts. Life Sci 29: 1277–1282, 1981 Mori T, Nagasawa H, Nakajima Y: Strain-difference in the induction of adenomyosis by intra-uterine pituitary grafting in mice. Lab Anim Sci 32: 40–41, 1982 Mori T, Nagasawa H: Alteration of the development of mammary hyperplastic alveolar nodules and uterine adenomyosis in SHN mice by different schedules of treatment with CB-154. Acta Endocrinol 107: 245–249, 1984 Nagasawa H, Konishi R, Naito T, Ohmiya S, Mori T: Relationship between mammary tumourigenesis and uterine adenomyosis in four strains of mice. In Vivo 1: 237–240, 1987 Nagasawa H, Yanai R, Taniguchi H, Tokuzen R, Nakahara W: Two-way selection of Swiss albino mice for mammary tumorigenesis: Establishment of two new strains (SHN and SLN). J Natl Cancer Inst 57: 425–430, 1976 Nagasawa H, Morii S, Tsubura A, Yanai R: Relative importance of genotype and type of mammary tumor virus on mammary tumorigenesis in mice. Eur J Cancer 15: 1119–1122, 1977 Nagasawa H, Aoki M, Mori T: Effects of different schedules of progesterone treatment on mammary tumorigenesis and uterine adenomyosis in SHN virgin mice. Life Sci 40: 2597–2602, 1987 Nagasawa H, Ishida M: Enhancement of spontaneous mammary tumorigenesis at advanced age in mice by temporary stimulation of mammary growth during youth. Life Sci 39: 389–393, 1986 Lanari C, Molinolo AA, Pasqualini CD: Induction of mammary adenocarcinoma by medroxyprogesterone acetate in BALB/c female mice. Cancer Letter 33: 215–223, 1986 Formelli F, Ronchi E, Di Fronzo G: Effect of medroxyprogesterone acetate on the growth of mouse transplanted tumors: Relation with hormone sensitivity. Anticancer Res 5: 313–320, 1985 Funes HC, Mèndez M, Madrigal PL. Alonso A: Treatment of advanced breast cancer with 2 different high doses of medroxyprogesterone acetate. In: Cavalli F, McGuire WL, Pannuti F, Pellegrini A, Robustelli Della Cuna G (eds) Proceedings of the International Symposium on Medroxyprogesterone Acetate. Excerpta Medica, Princeton, 1982, pp 215–223 Cavalli F, Goldhirsch A, Jungi WF, Martz G, Alberto P: Low-versus high-dose medroxyprogesterone acetate in the treatment of advanced breast cancer. In: Cavalli F, McGuire WL, Pannuti F, Pellegrini A, Robustelli Della Cuna G (eds) Proceedings of the International Symposium on Medroxyprogesterone Acetate. Excerpta Medica, Princeton, 1982, pp 224–233 Izuo M, Iino Y, Tominaga T, Nomura Y, Abe O, Enomoto K, Takatani O, Kubo K: Oral high dose medroxyprogesterone acetate therapy in advanced breast cancer: clinical and endocrine studies. In: Cavalli F, McGuire WL, Pannuti F, Pellegrini A, Robustelli Della Cuna G (eds) Proceedings of the International Symposium on Medroxyprogesterone Acetate. Excerpta Medica, Princeton, 1982, pp 250–263 Funes HC, Madrigal PL, Mangas GP, Mendiola C: Medroxyprogesterone acetate at two different high doses for the treatment of advanced breast cancer. In: Campio L, Robustelli Della Cuna G, Taylor RW (eds) Role of Medroxyprogesterone in Endocrine-Related Tumors, Vol. 2. Raven Press, New York, 1983, pp 77–83 Cavalli F, Goldhirsch A, Jungi F, Martz G, Mermillod B, Alberto P: Randomized trial for low-versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol 2: 414–419, 1984 Hedley D, Tattersall MHN, Dalgleish A, Coates A, Raghavan D, Fox R: Advanced breast cancer: Response to high dose oral medroxyprogesterone acetate. Aust NZ J Med 14: 251–254, 1984 Goss PE, Ashley S, Powles TJ, Coombes RC: High-dose oral medroxyprogesterone acetate in heavily pretreated patients with metastatic breast cancer. Cancer Treat Rep 70: 777–779, 1986 Nemoto T, Patel J, Rosner D, Dao T: Oral medroxyprogesterone in the treatment of metastatic breast cancer. J Surg Oncol 32: 211–213, 1986 Paridaens R, Becquart D, Michel J, Vanderlinden B, Longueville J, Majois F, Beauduin M, Focan C, Wildiers J, Lobelle JP, Arrigo C, Sylvester RJ, Heuson JC: Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. Anticancer Res 6: 1089–1094, 1986 Author information Authors and Affiliations Rights and permissions About this article Cite this article Nagasawa, H., Aoki, M., Sakagami, N. et al. Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice. Breast Cancer Res Tr 12, 59–66 (1988). https://doi.org/10.1007/BF01805741 Issue date: DOI: https://doi.org/10.1007/BF01805741